The CostEffective Way To Promote Your Health Business
HealthBusinessBuilder.Com

Health and Medical Guide to Kidney and Urinary System Disorders Kidneys and Urinary System Health information topics about Kidneys and Urinary System: Anatomy (Anatomy) Bladder Cancer (Bladder Cancer) Bladder Control (Urinary Incontinence) Bladder Diseases (Bladder Diseases) Colostomy (Ostomy) Cystitis (Interstitial Cystitis) Diabetic Kidney Problems (Diabetic Kidney Problems) Dialysis (Dialysis) End-Stage Renal Disease (Kidney Failure) ESRD (Kidney Failure) Hemodialysis (Dialysis, Kidney Failure) Ileostomy (Ostomy) Incontinence (Urinary Incontinence) Interstitial Cystitis (Interstitial Cystitis) Kidney Cancer (Kidney Cancer) Kidney Diseases (Kidney Diseases) Kidney Failure (Kidney Failure) Kidney Stones (Kidney Stones) Kidney Transplantation (Kidney Transplantation) Nephritis (Kidney Diseases) Neurogenic Bladder (Bladder Diseases) Ostomy (Ostomy) Overactive Bladder (Urinary Incontinence) Peritoneal Dialysis (Dialysis, Kidney Failure) Polycystic Kidney Disease (Kidney Diseases) Pyelonephritis (Kidney Diseases) Renal Cancer (Kidney Cancer) Renal Dialysis (Dialysis) Renal Disease (Kidney Diseases) Ureteral Cancer (Bladder Cancer) Urethral Cancer (Bladder Cancer) Urinary Bladder Cancer (Bladder Cancer) Urinary Incontinence (Urinary Incontinence) Urinary Tract Infections (Urinary Tract Infections) Urostomy (Ostomy) Wegener's Granulomatosis (Wegener's Granulomatosis) Wilms' Tumor (Wilms' Tumor   Urology / Nephrology News From Medical News Today Latest Health News and Medical News posted throughout the day, every day. Launch Of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France Fo... 6 Feb 2010 at 3:00am Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22... Kidney Cancer Drug Shows Promising Results 6 Feb 2010 at 2:00am The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology... Clinic Closure Leaves Indigent Dialysis Patients Looking For Treatment 5 Feb 2010 at 7:00am A clinic closure in Atlanta has patients and clinic officials struggling to find new providers that will treat low-income patients who need kidney dialysis, The Associated Press reports. "The treatment typically costs $40,000 to $50,000 a year, and Grady is just one of the struggling public hospitals cutting the service to reduce costs. Many indigent dialysis patients ... Paracetamol Protects Against Kidney Failure After Muscle Injury 5 Feb 2010 at 5:00am The commonly-used painkiller Paracetamol can protect against kidney failure after severe muscle injury, according to research at the University of Essex. One of the main causes of kidney failure affecting tens of thousands of people each year is a syndrome known as Rhabdomyolysis-Induced Renal Failure... Launch Of Ipsen's Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For T... 4 Feb 2010 at 3:00pm Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl® LP 22... Recordati : Silodosin Approved By The European Commission For The Treatment O... 4 Feb 2010 at 3:00am Recordati announces that it has been granted Marketing Authorization by the European Commission for the medicinal products Urorec® and Silodyx™ 4 mg, 8 mg, hard capsules, intended for treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Following national post-authorization procedures, as relevant, product launch could take place by end 2010 or beginning 2011... EMEA Gives Official Scientific Advice On Clinical Phase IIb Efficacy Study Of... 4 Feb 2010 at 3:00am Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced that it has received the official scientific advice from the European Medicines Agency (EMEA) on Hybrigenics' clinical development plan for inecalcitol in hormone-refractory prostate cancer patients... Mary Ann Liebert, Inc. Launch Groundbreaking Videourology Journal 4 Feb 2010 at 2:00am Videourology™ is the first and only videojournal for urologists, publishing fully peer-reviewed surgical and micro-invasive video demonstrations of the latest techniques and technologies used to optimize surgical patient care. Videourology™ is Part B of the respected Flagship publication Journal of Endourology published by Mary Ann Liebert, Inc... Stuart Dryer Honored As 2009 Fellow By American Association For The Advanceme... 4 Feb 2010 at 2:00am Stuart Dryer, the John and Rebecca Moores Professor of Biology and Biochemistry and biology department chair at the University of Houston, has been awarded the distinction of fellow from the American Association for the Advancement of Science (AAAS)... Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial For Nocturia 3 Feb 2010 at 5:00am Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the US... DSG Partners With Biotech Company To Battle Progressive And Chronic Kidney Di... 3 Feb 2010 at 3:00am DSG's eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG's eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle... Acetaminophen Protects Kidneys After Muscle Injury 2 Feb 2010 at 6:00am Severe muscle injuries - such as crush injuries suffered in earthquakes, car accidents and explosions, and muscle damage from excessive exercise or statin drug interactions - can cause life-threatening kidney damage. Treatment has been limited to intravenous fluids and dialysis, but a new study suggests that the commonly used pain reliever acetaminophen may protect the kidneys from damage... Pervasis Therapeutics Receives FDA Clearance For Pivotal Phase 3 Trial Of Vas... 2 Feb 2010 at 3:00am Pervasis Therapeutics, Inc. announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure. The agreement was made under the FDA's Special Protocol Assessment (SPA) procedure... Loyola Surgeon Uses Novel Technique To Perform Complicated Colon Surgery 2 Feb 2010 at 2:00am Janet Bunch of Chicago had just experienced another "excruciating" bout of diverticulitis, an inflammation of the pockets in the lining of the colon. "It was the second time in 19 months and the pain was worse than you could imagine," said Bunch, 64, a resident of Chicago. Mild cases of diverticulitis can be treated with changes in diet, rest and antibiotics... Fresenius Medical Care Sends Dialysis Supplies For Haiti Relief Effort 1 Feb 2010 at 6:00am Fresenius Medical Care North America (FMCNA), the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, is donating and delivering dialysis supplies to Haitians, at a time when relief supplies continue to be slow to reach those in need following a devastating earthquake and aftershock...